Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tinengotinib is a multikinase inhibitor targeting a series of kinases involved in cancer cell proliferation, angiogenesis, and regulation of immune response, including Aurora kinase A/B, Janus kinase (JAK1/2), fibroblast growth factor receptor (FGFR1/2/3), vascular endothelial growth factor receptors (VEGFRs), and other tyrosine kinases. Tinengotinib has shown good tolerability and preliminary efficacy in clinical trials in a variety of advanced solid tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $78 | In Stock | |
5 mg | $172 | In Stock | |
10 mg | $280 | In Stock | |
25 mg | $500 | In Stock | |
50 mg | $728 | In Stock | |
1 mL x 10 mM (in DMSO) | $155 | In Stock |
Description | Tinengotinib is a multikinase inhibitor targeting a series of kinases involved in cancer cell proliferation, angiogenesis, and regulation of immune response, including Aurora kinase A/B, Janus kinase (JAK1/2), fibroblast growth factor receptor (FGFR1/2/3), vascular endothelial growth factor receptors (VEGFRs), and other tyrosine kinases. Tinengotinib has shown good tolerability and preliminary efficacy in clinical trials in a variety of advanced solid tumors. |
Alias | TT00420, TT 00420 |
Molecular Weight | 394.86 |
Formula | C20H19ClN6O |
Cas No. | 2230490-29-4 |
Smiles | ClC=1C=CC=CC1C2=NC=3C(=NNC3C)NC=4C=C(N=CC24)N5CCOCC5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 25 mg/mL (63.31 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.